PapersPMID:34262417
Effect of Eurycoma longifolia standardised aqueous root extract-Physta® on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study.
- findings
- 6
- compound
- 1
- endpoints
- 6
- no difference found
- 5
- Study, every finding
- RCT · 3 months
- Dose studied, every finding
- 100 mg or 200 mg once daily after breakfast for 12 weeks
What moved
How to read these marks →- Increases total testosterone
moderate
“There was a significant increase (P < 0.05) in the total testosterone for Physta® 100 mg at week 12; for the Physta® 200 mg group, significant increase was seen at week 4 (P < 0.05) and maintained until week 12 (P < 0.001) compared to placebo.”
- Interests
- An author is affiliated with a producer
- Population
- Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, 35 per arm
What did not
“There were no significant between-group differences in the free testosterone levels for Physta® 100 and 200 mg compared to placebo at all-time points.”
- Interests
- An author is affiliated with a producer
- Population
- Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, 35 per arm
“There were no significant differences between groups in IGF-1 at baseline and week 12 in both Physta® groups compared to placebo, but in Physta® 100 mg group, IGF-1 levels significantly decreased (P < 0.05) at week 12 compared to baseline (Table 4).”
- Interests
- An author is affiliated with a producer
- Population
- Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, week 12 only
“There was no significant between-group differences in HbA1c for Physta® groups compared to placebo, but a significant (P < 0.05 and P < 0.01) within-group decrease in HbA1c was seen for both Physta® 200 mg and placebo groups, respectively.”
- Interests
- An author is affiliated with a producer
- Population
- Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, week 12 only
“There were no significant differences in the cortisol level in the Physta® groups at baseline and week 12 compared to placebo but a significant (P < 0.01) decrease from baseline is seen at week 12 in the Physta® 200 mg group.”
- Interests
- An author is affiliated with a producer
- Population
- Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, week 12 only
“There were no significant within-group or between-group differences in the vital signs, including BMI throughout the study for both Physta® groups.”
- Interests
- An author is affiliated with a producer
- Population
- Ageing men aged 50 to 70 years with baseline total testosterone below 300 ng/dL and BMI 18 to 30 kg/m2; Physta 100 mg and 200 mg arms each compared with placebo, safety assessment
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- healthy male volunteers aged 50 to 70 years with testosterone <300 ng/dL
- Participants
- 105
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 48